Global Influenza Diagnostics Market Overview:
Influenza diagnostics is critical for clinical management that enables medical professionals to quickly determine if a patient has the flu and if so. Accurate diagnose of influenza is infection control and public health actions to minimize the burden of influenza. Influenza testing detects the presence of the virus in a sample of respiratory secretions. The rapidly growing demand for point-of-care diagnostic is the major driving factor in the influenza diagnostics market growth globally. Moreover, the recent influenza outbreaks have prompted healthcare authorities to increase the capacity of influenza diagnosis globally. Some of the key players profiled in the study are Alere Inc. (United States), Abbott Laboratories (United States), bioMérieux SA (France), Thermo Fisher Scientific (United States), Roche Diagnostics (Switzerland), Bio-Rad Laboratories Inc. (United States), Quidel Corporation (United States), Becton, Dickinson and Company (United States), DiaSorin (Italy), A Scientific (United States) and Luminex Corporation (United States). According to Market Analyst at AMA, the Global Influenza Diagnostics market may see a growth rate of 6.86% and would reach the market size of USD923.14 Million by 2024.
On the basis of geography, the market of Influenza Diagnostics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
- Increasing Prevalence of Influenza across the World
- Growth in Research Funding for Influenza Diagnostics, Mostly in Developed Nations
- Growing Demand for Faster Diagnosis and Control of Influenza Globally
- Advancements in Genomic and Proteomic Technologies
- Rising Demand for Early Diagnosis and Control of Influenza
- Increasing Healthcare Costs Limiting the Usage of Novel Influenza Diagnostic Techniques
- The Growth in the Number of Approvals of Influenza Diagnostic Products by Regulatory Authorities
- Stringent Regulatory Framework
- The Dearth of Skilled Personnel to Handle Advanced Influenza Diagnostic Tools in Developing Nations
The FDA convened an advisory panel in June 2013 to discuss options to improve the regulation of the performance of RIDTs. A proposed order was published on 22 May 2014, and the final order published on 12 January 2017, reclassifying RIDTs from class I to class II medical devices, with additional requirements to comply with four new special controls.
Target Audience:Doctors, Physicians, Academic Institutes, Diagnostic Solution Providers, Research Institutes, Reference Laboratories, Diagnostic Suppliers, Home Health Agencies, Market Research and Consulting Firms and Others
Major Objectives Focused through this Study To define, describe, and forecast the Global Influenza Diagnostics market on the basis of product [Rapid Influenza Diagnostic Tests (RIDT), Direct Fluorescent Antibody (DFA) Tests, Molecular Diagnostic Tests, Traditional Diagnostic Tests, Viral Culture and Others] , application [Hospitals & Clinics, Research Laboratories and Other], key regions and end user
To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
To provide market size for various segments of the Influenza Diagnostics market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
To strategically profile the key players and analyzing their market shares and core competencies in the Influenza Diagnostics industry
To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market
Available Customization: Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Meridian Bioscience, Inc. (United States), Princeton BioMedtech corp. (United States) and Sekisui Medical Co., Ltd. (Japan).
** Confirmation on availability of data would be informed prior purchase
While framing the research framework, major and emerging players operating in the Influenza Diagnostics market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.